» Articles » PMID: 31709319

Cardioprotective Effects of VCP Modulator KUS121 in Murine and Porcine Models of Myocardial Infarction

Abstract

No effective treatment is yet available to reduce infarct size and improve clinical outcomes after acute myocardial infarction by enhancing early reperfusion therapy using primary percutaneous coronary intervention. The study showed that Kyoto University Substance 121 (KUS121) reduced endoplasmic reticulum stress, maintained adenosine triphosphate levels, and ameliorated the infarct size in a murine cardiac ischemia and reperfusion injury model. The study confirmed the cardioprotective effect of KUS121 in a porcine ischemia and reperfusion injury model. These findings confirmed that KUS121 is a promising novel therapeutic agent for myocardial infarction in conjunction with primary percutaneous coronary intervention.

Citing Articles

The effect of KUS121, a novel VCP modulator, against ischemic injury in random pattern flaps.

Yoshimoto K, Ikeguchi R, Noguchi T, Ando M, Sakamoto D, Iwai T PLoS One. 2024; 19(12):e0299882.

PMID: 39724048 PMC: 11671021. DOI: 10.1371/journal.pone.0299882.


The protein segregase VCP/p97 promotes host antifungal defense via regulation of SYK activation.

Shao Z, Wang L, Cao L, Chen T, Jia X, Sun W PLoS Pathog. 2024; 20(10):e1012674.

PMID: 39471181 PMC: 11548748. DOI: 10.1371/journal.ppat.1012674.


Targeting calpain-2-mediated junctophilin-2 cleavage delays heart failure progression following myocardial infarction.

Lahiri S, Lu J, Aguilar-Sanchez Y, Li H, Moreira L, Hulsurkar M J Mol Cell Cardiol. 2024; 194:85-95.

PMID: 38960317 PMC: 11519832. DOI: 10.1016/j.yjmcc.2024.06.011.


DUSP1 interacts with and dephosphorylates VCP to improve mitochondrial quality control against endotoxemia-induced myocardial dysfunction.

Zhu H, Wang J, Xin T, Chen S, Hu R, Li Y Cell Mol Life Sci. 2023; 80(8):213.

PMID: 37464072 PMC: 11072740. DOI: 10.1007/s00018-023-04863-z.


Discovery of Drug-Responsive Phenomic Alteration-Related Driver Genes in the Treatment of Coronary Heart Disease.

Guan S, Yu Y, Li B, Gu H, Chen L, Wang N Pharmgenomics Pers Med. 2023; 16:201-217.

PMID: 36945217 PMC: 10024908. DOI: 10.2147/PGPM.S398522.


References
1.
Ikeda H, Sasaoka N, Koike M, Nakano N, Muraoka Y, Toda Y . Novel VCP modulators mitigate major pathologies of rd10, a mouse model of retinitis pigmentosa. Sci Rep. 2014; 4:5970. PMC: 4122966. DOI: 10.1038/srep05970. View

2.
Saku K, Kakino T, Arimura T, Sunagawa G, Nishikawa T, Sakamoto T . Left Ventricular Mechanical Unloading by Total Support of Impella in Myocardial Infarction Reduces Infarct Size, Preserves Left Ventricular Function, and Prevents Subsequent Heart Failure in Dogs. Circ Heart Fail. 2018; 11(5):e004397. DOI: 10.1161/CIRCHEARTFAILURE.117.004397. View

3.
Hubbers C, Clemen C, Kesper K, Boddrich A, Hofmann A, Kamarainen O . Pathological consequences of VCP mutations on human striated muscle. Brain. 2006; 130(Pt 2):381-93. DOI: 10.1093/brain/awl238. View

4.
Imamura H, Nhat K, Togawa H, Saito K, Iino R, Kato-Yamada Y . Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. Proc Natl Acad Sci U S A. 2009; 106(37):15651-6. PMC: 2735558. DOI: 10.1073/pnas.0904764106. View

5.
Manno A, Noguchi M, Fukushi J, Motohashi Y, Kakizuka A . Enhanced ATPase activities as a primary defect of mutant valosin-containing proteins that cause inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Genes Cells. 2010; 15(8):911-22. DOI: 10.1111/j.1365-2443.2010.01428.x. View